The patent “Cardiac-valve prostesis” EP 1 690 515 B1, granted on 30th July 2008, of which Dr Burriesci is inventor, has been translated by SorinGroup into the sutureless surgical aortic valve Perceval™ S, that received the CE mark in 2011 and is now in the market. Contrary to standard surgical valves, the engineering solutions adopted in the stent of the Perceval™ S allow to deliver the compressed valve through the open aorta (using a transluminal delivery system) after removal of the native diseased leaflets, and deploy it into the anatomical region, where it self-anchors without requiring sutures. This new approach results in considerable shortening of the aortic cross-clamping and cardiopulmonary bypass time to less than 20 minutes, and represents a major advantage for the rapidly expanding group represented by high-risk patients or in complex operations.

The patent “Expandable prosthetic valve crimping device” EP 2 014 257 B1, granted on 8th September 2010, of which Dr Burriesci is inventor,has been translated into a crimping device adopted by SorinGroup to load the Perceval™ S autureless aortic valve prosthesis, and has already been used successfully in all the clinical implants of the above device.

 

Reviewer for the following institutions: - Medical Research Council UK - Heart Research UK - The Leverhulme Trust - the Ministry of Education, Greece

Reviewer for the following scientific journals: - the Philosophical Transactions of the Royal Society - Biomedical Materials - Medical Engineering & Physics - the Journal of Biomechanics - Experimental Techniques - Cardiovascular Engineering and Technology

Burriesci, G., Bergamasco, G. “Annuloplasty prosthesis with an auxetic structure”. European Patent n. EP 1 803 420 B1, granted on 1th July 2009. The concept of the patent: “Annuloplasty prosthesis with an auxetic structure” EP 1 803 420 B1, granted on 1th July 2009, of which Dr Burriesci is inventor, has recently been transferred into a novel device, that has already been granted the CE mark and FDA clearance, and has already been introduced in several countries, including USA with the commercial name MEMO 3D™ (distributed by SorinGroup SpA and CarboMedics Inc.). The early clinical results have proven the safety and efficacy of the device, and confirmed the validity of the technical solutions adopted in the design.

Masterclass on Artificial Heart Valves, London, UK

Visiting Academic at the University of Padua, Italy

Work on Transcatheter Aortic Valve described in the Heart Matters magazine, published by the British Heart Foundation (BHF), “Research that could be the future of mitral valve surgery”, by Doireann Maddock, July-August 2014.